Collectively, these findings emphasize the central immunoregulatory function of TGFβ1+ Tregs in CRC progression, highlighting them as potential therapeutic targets for modulating the tumor microenvironment and restoring antitumor immunity. The gene discussed is TGFB1; the disease is neoplasm.